Nasdaq Nordic Biotech Update March 2018

The past few years have witnessed a growing number of Nordic life sciences companies tap the capital markets of Copenhagen, New York and Stockholm. The paradigm for how Nordic life sciences companies have traditionally achieved financial exits for their investors in this region is changing, with more companies today seeking to publicly list their shares, sometimes even on more than one stock exchange. How are the life sciences capital markets working today, and what can be done to best prepare a Nordic life sciences company for a public listing? Last week Nasdaq was part of a regional seminar around this topic held in Copenhagen with contributions from leading industry experts, who examined the critical issues that executive management teams at life sciences companies must contemplate in advance of a public listing. Nasdaq has asked their two co-hosts Kristopher Brown from New York-based law firm – Dechert LLP and Thomas Holst Laursen from Danish law firm Plesner three quick questions about how they see opportunities for Nordic biotech companies in the Nordics to raise capital in the US and why?

Click here to read the full interview.